US House Speaker and others comment on ETHA reintroduction
29 March 2009
Speaker of the US House of Representives Nancy Pelosi (Democrat, California), along with Reps Eliot Engel (Democrat, New York) and Ileana Ros-Lehtinen (Republican, Florida), reintroduced the Early Treatment for HIV Act (ETHA) this week with a bipartisan group of 44 original co-sponsors. Speaker Pelosi released the following statement:
"Effective drug treatments have improved both health and quality of life for thousands of people living with HIV/AIDS. However, many uninsured, low-income HIV-positive individuals still do not have access to these life-saving medications because they generally do not meet Medicaid requirements until becoming disabled by full-blown AIDS," it said.
"Forcing people with HIV to wait for health care until their immune system is compromised by AIDS is bad health policy. The Early Treatment for HIV Act (ETHA) eliminates this harmful gap in the safety net. This change in Medicaid eligibility is long overdue. Studies show that passage of ETHA would not only significantly improve the health of people living with HIV, but also would reduce long-term health care costs as people stay healthy and active," it added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
US House Speaker and others comment on ETHA reintroduction
Speaker of the US House of Representives Nancy Pelosi (Democrat, California), along with Reps Eliot Engel (Democrat, New York) and Ileana Ros-Lehtinen (Republican, Florida), reintroduced the Early Treatment for HIV Act (ETHA) this week with a bipartisan group of 44 original co-sponsors. Speaker Pelosi released the following statement:
"Effective drug treatments have improved both health and quality of life for thousands of people living with HIV/AIDS. However, many uninsured, low-income HIV-positive individuals still do not have access to these life-saving medications because they generally do not meet Medicaid requirements until becoming disabled by full-blown AIDS," it said.
"Forcing people with HIV to wait for health care until their immune system is compromised by AIDS is bad health policy. The Early Treatment for HIV Act (ETHA) eliminates this harmful gap in the safety net. This change in Medicaid eligibility is long overdue. Studies show that passage of ETHA would not only significantly improve the health of people living with HIV, but also would reduce long-term health care costs as people stay healthy and active," it added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze